+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 18 Actively Recruiting clinical trials

S

Actively Recruiting

This trial studies adults aged 50 to under 80 with mild or moderate calcific aortic valve stenosis and elevated lipoproteina levels. Researchers are assessing the safety, tolerability, and ability of pelacarsen TQJ230 given once monthly by injection to slow the progression of this heart valve condition. The study compares pelacarsen to a placebo in a randomized, double-blind design. Participants receive either pelacarsen 80 mg or a matching placebo as a subcutaneous injection monthly. They continue treatment and monitoring for up to 36 months to observe changes in heart valve narrowing and calcium buildup. The study also tracks lipoproteina levels and clinical heart-related events during this period. Throughout the study, participants will have regular assessments including imaging to measure aortic valve function and calcium score, blood tests for lipoproteina, and monitoring for safety. The main outcomes analyzed after 36 months include changes in valve jet velocity and calcium score, alongside clinical events. Participants remain under medical care while being observed for any effects of the study drug or placebo.

Age: 50Years - 80YearsAll GendersPhase 2
140 locations
R

Actively Recruiting

Researchers are evaluating the efficacy and safety of orelabrutinib, a brain-penetrating BTK inhibitor, in people with Primary Progressive Multiple Sclerosis PPMS. This is a Phase 3, randomized, double-blind, parallel-group, multicenter study comparing orelabrutinib with a placebo. Approximately 705 participants aged 18 to 60 with documented disability progression will be enrolled globally. Participants will be randomly assigned in a 21 ratio to receive either oral orelabrutinib or a placebo. Treatment will last approximately 30 to 60 months, with a minimum duration of 12 months. The study includes two groups one receiving orelabrutinib and the other receiving placebo, both taken orally. Throughout the study, participants will undergo regular assessments including disability progression measurements confirmed over 12 and 24 weeks, MRI scans, and tests such as the 9-hole Peg Test and Timed 25-Foot Walk Test. Safety will be monitored continuously, and the primary outcome is time to confirmed disability progression over about 120 weeks. Participants will be followed up for up to 5 years to evaluate the treatment effects and safety.

Age: 18Years - 60YearsAll GendersPhase 3
83 locations
E

Actively Recruiting

Researchers are evaluating orelabrutinib, a brain-penetrating BTK inhibitor, in patients with non-active Secondary Progressive Multiple Sclerosis SPMS. This phase 3, randomized, double-blind, multicenter study compares the effects and safety of orelabrutinib against placebo. About 990 participants will be enrolled globally and randomly assigned in a 21 ratio to receive either orelabrutinib or placebo. The study aims to assess disability progression and other neurological outcomes in this population. Participants will undergo a screening period of up to 4 weeks before starting treatment. The treatment period varies individually, lasting approximately 24 to 60 months, with a minimum of 12 months of double-blind treatment where participants receive either daily orelabrutinib orally or placebo. Participants showing confirmed disability progression at 24 weeks may continue in a 2-year open-label phase receiving orelabrutinib. After treatment ends, a 4-week safety follow-up is conducted unless participants join a long-term safety study where treatment continues. During the study, participants will be monitored regularly to track disability progression confirmed over 24 weeks and other outcomes including MRI lesions, relapse rates, and functional test results. Safety and tolerability of orelabrutinib are also assessed throughout up to about 120 weeks. All active participants will have a final study visit near the study end date, with additional safety follow-up visits when applicable. The total study duration can extend up to several years depending on individual participation and treatment phase.

Age: 18Years - 60YearsAll GendersPhase 3
90 locations
P

Actively Recruiting

Researchers are evaluating the safety, tolerability, and effects of ORX750 in adults with Narcolepsy Type 1 NT1, Narcolepsy Type 2 NT2, and Idiopathic Hypersomnia IH. These rare conditions cause excessive daytime sleepiness and affect daily activities such as school, work, and driving. The study aims to understand how ORX750, which mimics the brain protein orexin that helps maintain wakefulness, impacts sleepiness and other symptoms in these conditions. Participants will receive either ORX750 capsules or matching placebo capsules in a randomized, double-blind setup. The study assesses multiple groups those with NT1, NT2, and IH. The treatment and monitoring will occur over a period of up to 35 days, including evaluation of plasma drug levels and sleepiness measures. During the study, participants will undergo safety assessments including monitoring for adverse events, laboratory tests, vital signs, ECGs, and suicidal ideation screening up to day 35. Researchers will also measure sleepiness using the Maintenance of Wakefulness Test and the Epworth Sleepiness Scale. The total study duration for each participant is about five weeks, with careful observation of how the body processes ORX750 and its effects on daytime alertness.

Age: 18Years - 65YearsAll GendersPhase 2
37 locations
A

Actively Recruiting

Idiopathic Hypersomnia IH is a condition where adults feel extremely sleepy during the day, especially in the morning, even after sleeping a lot at night. This condition can cause difficulty waking up, trouble focusing, and symptoms like dizziness. Researchers are studying TAK-360, a drug that acts like orexin, a brain chemical that helps keep people awake. The study aims to understand how safe and tolerable TAK-360 is for adults with IH and to find the right dose to help with wakefulness. Participants in the study will be randomly assigned to receive either TAK-360 tablets or placebo tablets that look the same but contain no active medicine. Both treatments will be taken orally for 4 weeks. The study uses a double-blind design, meaning neither participants nor researchers know who receives the drug or placebo, to fairly evaluate the effects of TAK-360. During the study, participants will be monitored for safety and side effects up to 8 weeks. Researchers will measure changes in daytime sleepiness using the Epworth Sleepiness Scale and symptoms using the Idiopathic Hypersomnia Severity Scale at the start and after 4 weeks. The trial will also track any treatment-emergent adverse events. The total participation time may include screening, treatment, and follow-up assessments over several weeks.

Age: 18Years - 70YearsAll GendersPhase 2
29 locations
L

Actively Recruiting

Researchers are evaluating the safety and tolerability of TAK-861 in people with narcolepsy type 1 NT1. This study focuses on participants who have already been exposed to TAK-861 doses in previous clinical trials. The goal is to monitor how TAK-861 affects symptoms such as excessive daytime sleepiness and cataplexy episodes over a long period. All participants in this trial will receive TAK-861 tablets. Those who previously received a placebo will be randomly assigned to one of the TAK-861 dose groups. The study is a long-term extension conducted worldwide and is expected to last approximately five years or until the product is approved or the study is stopped. Participants may switch doses as needed and will attend multiple clinic visits, some of which can be done at home. Throughout the trial, participants will be regularly assessed for safety by tracking any treatment-emergent adverse events. Researchers will also measure changes in sleep latency, sleepiness scores, and cataplexy rates compared to baseline data from earlier trials. Follow-up assessments will take place four weeks after the final dose to monitor ongoing effects and ensure participant safety.

Age: 16Years - 70YearsAll GendersPhase 2Phase 3
52 locations
R

Actively Recruiting

Researchers are evaluating remibrutinib for its effectiveness and safety in treating patients with secondary progressive multiple sclerosis SPMS. This Phase III, randomized, double-blind, placebo-controlled study involves about 1275 participants who meet specific criteria, including an SPMS diagnosis and disability progression. The trial is designed to provide detailed data on remibrutinibs impact compared to placebo, with a focus on disability progression and other neurological measures. Participants are randomly assigned to receive either remibrutinib or a matching placebo tablet during the Core Part of the study, which is event-driven and double-blind. Following this, there is an Extension Part where all participants receive open-label remibrutinib tablets. Treatment is oral and involves ongoing monitoring to assess long-term effects and safety. Throughout the study, participants will undergo regular assessments including disability evaluations using the Expanded Disability Status Scale EDSS, Timed 25-Foot Walk, 9-Hole Peg Test, and cognitive testing with the Symbol Digit Modalities Test SDMT. Brain imaging will be used to track lesion development and brain atrophy. Safety will be closely monitored by recording adverse events. The total participation may span up to approximately five years, covering both core and extension phases.

Age: 18Years - 65YearsAll GendersPhase 3
296 locations
R

Actively Recruiting

Researchers are evaluating clemizole HCl as an additional treatment for children and adults with Lennox-Gastaut syndrome LGS, a severe form of epilepsy. This phase 3 study is randomized, double-blind, and placebo-controlled, aiming to assess both the safety and effectiveness of clemizole HCl when added to current therapies. The study includes an Observational Period, a Double-Blind Period, and an optional Open-Label Extension Period to gather comprehensive data over time. Participants will be randomly assigned to receive either clemizole HCl or a placebo, both given as oral solutions. After completing the Double-Blind Period, eligible participants may choose to continue treatment with clemizole HCl in the Open-Label Extension Period for up to three years. This design helps researchers compare outcomes between the study drug and placebo, and to observe long-term effects of clemizole HCl. During the study, participants will be monitored regularly to measure changes in seizure frequency and severity, using tools like the CMMS-28 scale. Other assessments include global impression scores from clinicians and caregivers, quality of life evaluations, and safety monitoring for adverse events. The primary outcome focuses on seizure changes over 16 weeks, while secondary outcomes look at seizure-free days, overall impact, and safety throughout the trial duration, potentially spanning up to nearly five years.

Age: 2Years - 55YearsAll GendersPhase 3
71 locations
S

Actively Recruiting

This research aims to identify new biomarkers linked to synaptic damage in Multiple Sclerosis MS and to study the mechanisms that contribute to this damage. It involves both prospective and retrospective observation over about five years, analyzing blood and cerebrospinal fluid samples taken for diagnostic reasons. The study includes patients with MS, other chronic neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Alzheimers disease, Parkinsons disease, and healthy subjects as control groups. Participants undergo procedures including lumbar puncture and blood sampling to measure microRNAs, cytokines, chemokines, growth factors, neuronal damage markers like tau proteins and neurofilaments, mitochondrial markers lactate, and free d-amino acids. The study also evaluates synaptic changes using an ex vivo chimeric model of MS with patch-clamp techniques and conducts genotyping to find gene variants associated with synaptic transmission alterations and clinical parameters. Throughout the study, researchers monitor these biomarkers and genetic factors to predict disease progression and identify potential therapeutic targets. Participants provide samples for various laboratory analyses, including SNPs analysis, and clinical assessments such as the Expanded Disability Status Scale EDSS and disease activity indices. The studys main outcome is to identify predictive biomarkers using the ex vivo model, with secondary goals to find new therapeutic targets for MS.

Age: 18Years - 65YearsAll Genders
1 location
S

Actively Recruiting

Healthy Volunteer

Neurodegenerative disorders such as Parkinsons disease, Alzheimers disease, Frontotemporal dementia, and Amyotrophic Lateral Sclerosis involve the buildup of misfolded proteins that affect nerve cell function and survival. Researchers are studying protein complexes in body fluids as potential biomarkers to help with early diagnosis, prognosis, and treatment management of these disorders. This observational study aims to collect clinical, genetic, and biofluid data from patients and healthy individuals to identify and validate these biomarkers. Participants will undergo genetic testing including whole genome and whole exome sequencing to analyze DNA for variants related to their specific condition. Samples of cerebrospinal fluid CSF, plasma, serum, and blood cells will be collected for analysis. The study involves collaboration between two centers focusing on patient stratification, sample collection, bioinformatics, and biological validation using human brain tissue and neuron cultures derived from induced pluripotent stem cells. During the study, participants will be evaluated for motor and cognitive symptoms using clinical scales such as the Hoehn and Yahr score, MDS-UPDRS, MOCA, and others over two years. Researchers will analyze protein complexes in CSF and plasma and correlate findings with genetics and clinical data. The biological effects of identified protein complexes on neuron viability will also be assessed. Participant involvement includes clinical assessments, sample donations, and genetic testing, with ongoing monitoring throughout the study period.

Age: 20Years +All Genders
1 location

1-10 of 18

1